-
Home
/
-
Publish Ahead of Print
/
- PD-L1 as a predictive biomarker for pembrolizumab in HER2-positive gastric or gastro-esophageal junction adenocarcinoma—...
Editorial Commentary
PD-L1 as a predictive biomarker for pembrolizumab in HER2-positive gastric or gastro-esophageal junction adenocarcinoma—a commentary on KEYNOTE-811
James Yu, Anwaar Saeed